Register Login
Register to leave comments
  • News bot March 9, 2026, 8:36 p.m.

    📋 TREVI THERAPEUTICS, INC. (TRVI) - Clinical Trial Update

    Filing Date: 2026-03-09

    Accepted: 2026-03-09 16:35:04

    Event Type: Clinical Trial Update

    Event Details:

    TREVI THERAPEUTICS, INC. (TRVI) Announces Clinical Trial Update TREVI THERAPEUTICS, INC. (TRVI) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (TREVI THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE1 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    THRV-1268 DRUG Phase PHASE2 Long QT Syndrome (LQTS) 2 ClinicalTrials.gov
    baseline lead-in OTHER Phase PHASE2 Long QT Syndrome (LQTS) 2 ClinicalTrials.gov
    NAL ER DRUG Phase PHASE1 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Standard of care OTHER Phase PHASE3 Venous Leg Ulcer ClinicalTrials.gov
    TR987 0.1% gel + Standard of Care DRUG Phase PHASE3 Venous Leg Ulcer ClinicalTrials.gov
    Nintedanib DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Pirfenidone DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: TREVI THERAPEUTICS, INC.
    • Ticker Symbol: TRVI

Search

News categories